Navigation Links
TG02 Potently Inhibits the Proliferation and Survival of Multiple Myeloma Cell Lines through Depletion of the Key Survival Protein MCL-1
Date:4/5/2013

of inhibiting important cyclin dependent kinases equipotently with JAK2, FLT3, and ERK5 inhibition. TG02 exerts its antitumor activity via its potent CDK9 inhibition, which leads to the depletion of key survival proteins, such as Mcl-1, resulting in p53-independent apoptosis of a wide range of tumor cells. TG02 development will initially focus on the treatment of hematologic malignancies, including multiple myeloma (MM) and chronic lymphocytic leukemia (CLL), because of the consistent antitumor activity that was observed across a broad spectrum of hematologic cancer models, including those resistant to currently available therapies. In these models, TG02 demonstrated both single agent activity and synergy when administered with current standard of care therapies. Subsequent development will focus on an important group of solid tumors with unmet medical need, such as small cell lung cancer, triple negative breast cancer, and melanoma, which will also benefit from this mechanism of action, complemented with the benefits of inhibiting both JAK2 and ERK5. These pathways affect disease progression and survival in hematologic malignancies and solid tumors.

TG02 is currently being evaluated in two separate phase I clinical trials in patients with MM and CLL in the United States. Subsequent phase Ib clinical studies of TG02 in combination with other agents are planned for later in 2013.

In early 2010, TG02 was selected by the Multiple Myeloma Research Foundation as a winner of its Biotech Investment Award, which represents a multi-year research grant commitment to fund the early-stage drug development of novel compounds that show potential in treating MM.

About Tragara
Tragara Pharmaceuticals, Inc. is a privately held pharmaceutical company based in San Diego, Calif. The company is focused on the clinical and commercial development of proprietary medicines for the treatment of cancer. TG02 is a unique, oral multi-kinase inhibitor whi
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Bloodstream scavenger inhibits clotting without increased bleeding
2. Molecule found that inhibits recovery from stroke
3. New monoclonal antibody inhibits tumor growth in advanced solid tumors in phase I clinical trial
4. Kentucky team inhibits Alzheimers biomarkers in animal model by targeting astrocytes
5. CWRU School of Medicine researchers discover gene that permanently stops cancer cell proliferation
6. Vaccine yielded encouraging long-term survival rates in certain patients with NSCLC
7. Cancer Care Costs Higher in U.S. Than Europe, But Survival Longer
8. Adding drug to standard chemotherapy provides no survival benefit for older lung cancer patients
9. Hispanics Seem to Have Better Odds of Lung Cancer Survival
10. Equal access to care helps close survival gap for young African-American cancer patients
11. Heart Attack Survival Varies Widely Among Hospitals, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Isabel Healthcare will ... Professions (ASAHP) Conference on October 22-24 in Las Vegas, ... in a panel discussion on Technology in Health Professions ... provides a diagnostic decision support tool and clinical education ... of students and clinical learners. The Isabel tools help ...
(Date:10/22/2014)... The Louis W. Sullivan ... to distribute health information technology innovation to transform ... the development of six key guiding principles of ... healthcare. These are an expansion of the Institute ... that is respectful of and responsive to individual ...
(Date:10/22/2014)... Texas (PRWEB) October 22, 2014 ... of completing their continuing education at home or ... have access to 20 brand new, premium Seminar-on-Demand ... robust catalog of over 2,000 hours ... fully customize their educational experience. With such a ...
(Date:10/22/2014)... 22, 2014 Akeso Biomedical, Inc. ... the treatment of bacterial infections, microbial biofilms, and chronic ... its board of directors. , Dr. Sinskey ... at The Massachusetts Institute of Technology, or MIT. He ... 1968. Dr. Sinskey also holds positions as Co-Director of ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, 2014 ... fertilization (IVF) -- the incubation of embryos in a laboratory ... the vagina, new research suggests. Scientists from the United ... might sharply cut costs for pricey IVF procedures among certain ... those who don,t live near big-city assisted reproduction centers, the ...
Breaking Medicine News(10 mins):Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... , TONBRIDGE, England, Sept. ... innovation of the past 150 years, by leading figures in the ... the electric light bulb and penicillin in a star-studded competition organised ... The final four inventions went head-to-head in a live debate, with ...
... , , MIDDLETOWN, Conn., Sept. ... Blue Cross and Blue Shield Foundation grant to the national ... $37,500 to fund the "Family Link" program here in Connecticut. ... community-based network that connects parents of children with diabetes with ...
... , , ... (AFA) today applauded Senate Finance Committee Chairman Max Baucus (D-MT) ... including cognitive impairment screening for Medicare beneficiaries in Baucus, healthcare ... , , AFA had pressed for cognitive ...
... , , , MINNEAPOLIS, Sept. ... health by helping yogurt lovers regulate digestive health without compromising calorie ... Available in three delicious flavors -- Honey Vanilla, Strawberry Banana and ... Light is an easy way to help keep your digestive health ...
... , , , NEW YORK, Sept 17 ... today announced that it will host The Runyon 5K , ... on Sunday, November 15th 2009. Proceeds from the event, the first of ... scientists carrying out innovative research for all types of cancer. , ...
... Sept. 17, 2009 The Wellcome Trust and Merck ... MSD Wellcome Trust Hilleman Laboratories ( www.hillemanlaboratories.in ), the ... with a not-for-profit mission to focus on developing affordable ... The joint venture marks the first ...
Cached Medicine News:Health News:Contraceptive Pill Named the Greatest Pharmacy Invention of the Last 150 Years in Chemist+Druggist Competition 2Health News:Anthem Blue Cross and Blue Shield Foundation Grant Supporting American Diabetes Association's 'Family Link' Program In Connecticut 2Health News:Anthem Blue Cross and Blue Shield Foundation Grant Supporting American Diabetes Association's 'Family Link' Program In Connecticut 3Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Screening for Medicare Beneficiaries in Senate Finance Committee Health Reform Proposal 2Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Screening for Medicare Beneficiaries in Senate Finance Committee Health Reform Proposal 3Health News:Photos: New Yoplait(R) YoPlus(TM) Light... A Delicious Way to Regulate Digestive Health With Fewer Calories 2Health News:Photos: New Yoplait(R) YoPlus(TM) Light... A Delicious Way to Regulate Digestive Health With Fewer Calories 3Health News:Damon Runyon 5K Run/Walk at Yankee Stadium to Benefit Cancer Research 2Health News:Damon Runyon 5K Run/Walk at Yankee Stadium to Benefit Cancer Research 3Health News:Damon Runyon 5K Run/Walk at Yankee Stadium to Benefit Cancer Research 4Health News:Wellcome Trust and Merck launch joint venture to develop affordable vaccines 2Health News:Wellcome Trust and Merck launch joint venture to develop affordable vaccines 3Health News:Wellcome Trust and Merck launch joint venture to develop affordable vaccines 4
(Date:10/22/2014)... HOUSTON , Oct. 22, 2014  Charlene Vernak, RPh, ... York , recently was awarded the George Roentsch ... Vernak received the award in Houston ... The scholarship is awarded annually to an independent pharmacist ... nature of George Roentsch , a well-known pharmacist ...
(Date:10/22/2014)... Oregon , October 22, 2014 ... "Global Disposable Gloves Market (Product type, Form, End user, ... Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and ... global disposable gloves market. Based on key trends tracked, ... be valued at $7.9 billion by 2020, registering a ...
(Date:10/22/2014)... , Oct. 21, 2014  Early symptoms ... subtle or unnoticed, but new technology, coupled with ... and leading to earlier detection of eye diseases, ... 29 million Americans. If left untreated, these diseases ... blindness. Recently, optometric researchers have ...
Breaking Medicine Technology:PCCA Awards Charlene Vernak, RPh, the George Roentsch Scholarship 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 3
... Delcath Systems, Inc. (Nasdaq: DCTH ), a developmental stage ... that it will open the NASDAQ stock market on Friday, ... Times Square in New York City will be broadcast ... NASDAQ webcam. The live ceremony, including President and Chief Executive Officer ...
... Inc. (Nasdaq: MYL ) today announced that it increased the ... pricing.  Mylan priced $550 million aggregate principal amount of ... and $700 million aggregate principal amount of 7.875% Senior ... to use approximately $1.0 billion of the net proceeds ...
Cached Medicine Technology:Delcath's Eamonn Hobbs to Ring NASDAQ Opening Bell 2Mylan Announces Upsizing and Pricing of Senior Notes 2Mylan Announces Upsizing and Pricing of Senior Notes 3
Anesthesia Associates Nerve Stimulator Model AA 1050...
... A range of easy to use instruments ... nerve locator, peripheral nerve stimulator, and muscle ... pole, plastic hub, and pencil point needles., ... inexpensive, practical and easy to use stimulator, ...
... nerve stimulator from B. Braun Medical. It ... stimulator functionality for over 10 years. , ... a unique, under-the-glove hand held remote current ... It allows the anesthesia provider operating solo ...
... the original MS-III design the ... enhanced keypad and ... MiniStim® MS-IV peripheral nerve stimulator ... monitoring in operating room, post ...
Medicine Products: